Sugi Predict

Sugi Predict / Targets / PARN

PARN

Poly(A)-specific ribonuclease PARN · O95453 · PARN on Sugi Atlas →

484 patent compounds predicted against PARN, 320 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8798601 SCHEMBL8798601 0.76 1/20
SCHEMBL4420441 SCHEMBL4420441 0.72 1/20
SCHEMBL13861874 SCHEMBL13861874 0.70 1/20
SCHEMBL554897 SCHEMBL554897 0.61 1/20
SCHEMBL28752105 SCHEMBL28752105 0.61 1/20
SCHEMBL27600280 SCHEMBL27600280 0.61 1/20
SCHEMBL28749916 SCHEMBL28749916 0.61 1/20
SCHEMBL9391031 SCHEMBL9391031 0.59 1/20
SCHEMBL16058255 SCHEMBL16058255 0.58 1/20
SCHEMBL27586852 SCHEMBL27586852 0.58 1/20
SCHEMBL1713107 SCHEMBL1713107 0.57 1/20
SCHEMBL7974027 SCHEMBL7974027 0.57 1/20
SCHEMBL16312820 SCHEMBL16312820 0.57 1/20
SCHEMBL27583105 SCHEMBL27583105 0.57 1/20
SCHEMBL3621012 SCHEMBL3621012 0.57 1/20
SCHEMBL7975271 SCHEMBL7975271 0.56 1/20
SCHEMBL16076166 SCHEMBL16076166 0.56 1/20
SCHEMBL11884633 SCHEMBL11884633 0.56 1/20
SCHEMBL7975254 SCHEMBL7975254 0.55 1/20
SCHEMBL7988101 SCHEMBL7988101 0.55 1/20

Clinical trials — most relevant to PARN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations PHASE1/PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) PHASE1/PHASE2RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer PHASE2COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction PHASE1ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer PHASE1COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives nanRECRUITING
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure nanRECRUITING
PPK Study Based on Quantitative Pharmacology in Patients With Pamipril nanUNKNOWN
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171 nanUNKNOWN
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PARN binder may also engage these)

ProteinNameSimilarity
Q5RC51 — 1.000 Q5RC51 →
Q8VDG3 — 0.999 Q8VDG3 →
P69341 — 0.996 P69341 →
Q90ZA1 — 0.983 Q90ZA1 →
Q7ZU92 — 0.976 Q7ZU92 →
Q6NYU2 — 0.969 Q6NYU2 →
Q5BJZ6 — 0.968 Q5BJZ6 →
F1N9S8 — 0.967 F1N9S8 →
HELZ Probable helicase with zinc finger domain 0.967 landscape →
Q4A1L5 — 0.967 Q4A1L5 →
Q6GR37 — 0.966 Q6GR37 →
Q91XJ1 — 0.966 Q91XJ1 →
Q5F480 — 0.966 Q5F480 →
F1QDI9 — 0.965 F1QDI9 →
Q80YV4 — 0.964 Q80YV4 →
Q6DFV5 — 0.964 Q6DFV5 →
Q5U252 — 0.964 Q5U252 →
Q9NXL9 — 0.964 Q9NXL9 →
Q4A1L4 — 0.963 Q4A1L4 →
Q5R878 — 0.963 Q5R878 →
Q6PDL0 — 0.963 Q6PDL0 →
Q9JM13 — 0.963 Q9JM13 →
O60879 — 0.963 O60879 →
Q8NFZ0 — 0.962 Q8NFZ0 →
Q4A1L3 — 0.962 Q4A1L3 →
Q9ESL4 — 0.962 Q9ESL4 →
ERCC4 DNA repair endonuclease XPF (EC 3.1.-.-) (DNA 0.962 landscape →
AASDHPPT L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 0.962 landscape →
Q99NI4 — 0.962 Q99NI4 →
P61798 — 0.962 P61798 →